Your session is about to expire
← Back to Search
Biological
Platelet Rich Plasma Injection for Knee Osteoarthritis
Phase < 1
Waitlist Available
Led By Christian Wuescher, MD
Research Sponsored by University of Toledo Health Science Campus
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing PRP injections for patients with knee osteoarthritis who haven't found relief from other treatments. The goal is to use the body's natural healing abilities by injecting concentrated blood platelets into the knee to reduce pain and improve function. PRP injections have been increasingly studied and used for knee osteoarthritis, showing potential to reduce pain and improve function.
Eligible Conditions
- Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Correlation of outcomes with whole blood and platelet rich plasma (PRP) concentrations
Functional status outcome using the Timed up and go (TUG) test, 1 year
Functional status outcome using the Timed up and go (TUG) test, 3 months
+9 moreSecondary study objectives
Correlation of outcomes and patient demographics and co-morbidities
Emergency room utilization, 1 year
Emergency room utilization, 3 months
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants receiving a platelet rich plasma injectionExperimental Treatment1 Intervention
All patients in the study will be receiving a platelet rich plasma injection, and we will be following their clinical outcomes
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Platelet Rich Plasma Injection
2021
Completed Early Phase 1
~50
Find a Location
Who is running the clinical trial?
University of Toledo Health Science CampusLead Sponsor
41 Previous Clinical Trials
16,371 Total Patients Enrolled
1 Trials studying Osteoarthritis
60 Patients Enrolled for Osteoarthritis
Christian Wuescher, MDPrincipal InvestigatorUniversity of Toledo
Ashley Schneider, MDStudy DirectorUniversity of Toledo
Leah Wuescher, PhDStudy DirectorUniversity of Toledo
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a diagnosed rheumatologic disease that affects your knee.You have had surgery on your knee in the past.Your knee pain is not caused by nerve issues, pain referred from other areas, or an infection in the knee joint.You have a serious heart condition.Your immune system is weakened or suppressed.You are currently taking medication to prevent blood clots or to stop platelets from sticking together.You have a history of a serious mental illness with hallucinations or delusions.You have had knee pain or swelling for more than 3 months.You have knee pain that is rated as at least a 3 out of 10 on a pain scale.You are currently using drugs through intravenous (IV) injection.You recently had a serious knee injury that caused pain and swelling.You have received a knee injection in the past 3 months.
Research Study Groups:
This trial has the following groups:- Group 1: Participants receiving a platelet rich plasma injection
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.